// App-Quantinova.ai

P184 : A 24-month prospective psoriatic arthritis observational study of persistence of treatment - interim analysis of baseline characteristics

Researchers

Presenter

  • Jacques Morel

Principal Investigators

  • Lorenzo Dagna

  • Beatriz Joven Ibáñez

  • Thorsten Holzkaemper

  • Celine El Baou

  • Leonore Unger

  • Angelo Semeraro

  • Nicola Gullick

  • Tamas Treuer

Medical Centers

  • Rheumatology, 1. Medizinische Klinik, Klinikum Dresden, Friedrichstadt, Dresden, Germany

  • Rheumatology, OU Reumatologia, Presidio ospedaliero Valle d’Itria, Piazza San Francesco da Paola 1, Martina Franca, Italy

  • Rheumatology, University of Warwick, Warwick Medical School, Coventry, United Kingdom

  • Unit of Rheumatology, Immunology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Milan, Italy

  • Rheumatology Immunology, University Montpellier, montpellier, France

  • University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom

  • Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain

  • Vita-Salute San Raffaele University, Milan, Italy

  • Rheumatology, Montpellier School of Medicine, University of Montpellier, Montpellier, France

Locations

  • Germany

  • United Kingdom

  • Italy

  • Spain

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Interleukin 12

  • Interleukin-23

  • Janus kinase

Drug/Treatment

  • ABT-494

  • Tasocitinib

  • secukinumab

  • Ustekinumab

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

  • guselkumab (IV)

  • IL-12

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved